Trial Profile
A Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects With Chronic Sinusitis (LANTERN Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Mometasone (Primary)
- Indications Chronic sinusitis; Rhinosinusitis
- Focus Registrational; Therapeutic Use
- Acronyms LANTERN
- Sponsors Lyra Therapeutics
- 10 Sep 2022 According to a Lyra Therapeutics media release, data from this study was presented at the 68th Annual Meeting of the American Rhinologic Society (ARS)
- 10 Sep 2022 Results published in Lyra Therapeutics Media Release.
- 29 Aug 2022 According to a Lyra Therapeutics media release, data from this study will be presented at the 68th Annual Meeting of the American Rhinologic Society (ARS)